XSTO
SEZI
Market cap48mUSD
Oct 09, Last price
2.92SEK
1D
-0.68%
1Q
-30.14%
Jan 2017
-55.91%
IPO
-50.85%
Name
Senzime AB (publ)
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Uppsala, Sweden, Senzime AB (publ) is a medical technology company founded in 1999, specializing in the development and commercialization of advanced patient monitoring systems. These systems are designed to oversee individuals under anesthesia across a wide geographic reach, including Europe, Oceania, Asia, Canada, and the United States. A key offering is the TetraGraph monitor, which precisely stimulates, measures, analyzes, and displays muscle function for surgical patients administered neuromuscular blocking agents. The system includes the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. Its TetraConnect data management portal allows clinicians to easily access, view, and export records from the TetraGraph in PDF or Excel format. Additionally, TetraGraph Device Connectivity facilitates the transfer of data from the monitor to other patient monitoring systems. A specific TetraGraph Philips Interface enables the direct transmission of neuromuscular monitoring parameters (TOFC, TOFR, PTC, and TOF bars) to Philips patient monitors, displaying readings on the Philips Intellivue Monitor. The company's portfolio also includes the CliniSenz Analyzer, developed for continuous postoperative patient surveillance in hospital settings. Furthermore, the Onzurf Probe is a sterile, CE-marked, single-use micro-dialysis product that allows for continuous sampling from gastrointestinal organs like the esophagus, stomach, and liver. Senzime AB (publ) has entered into a strategic license and connectivity agreement with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to connect directly with Masimo's Root monitoring system and its digital hubs for seamless integration with hospital clinical information systems and electronic health records.
Key people
Philip Siberg
Chairman of the Board · since 2016
Chief Executive Officer · since 2019
Chief Executive Officer · since 2013
Erik Bergman
Chief Financial Officer · since 2019
Anders Jacobson
Chief Technology Officer · since 2016
David R. Hampton
Chief Scientific Officer, Product Development
Catrin Molund
Vice President of Marketing and Business Development · since 2019
Chris Estes
General Manager, US Operations · since 2020
Anders Selin
Vice President of Sales · since 2019
Pernilla Abrahamsson
Marketing and Sales Director
Rianne Lundqvist Waninge
Application Scientist
Sara Vazda
Clinical Development Specialist
Sorin J. Brull
Director · since 2016
Headquarters & legal address
ULLS VÄG 41
Uppsala, C 756 51
SE
Uppsala, C 756 51
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||